References
- Julian Gardiner, Jude Oben, Alastair Sutcliffe. Obesity as a driver of
international differences in COVID-19 death rates. Diabetes Obes
Metab. 2021 Jul;23(7):1463-1470.
- Zhang X, Zhang W, Chen S. Shanghai’s life-saving efforts against the
current omicron wave of the COVID-19 pandemic. Lancet 2022; 399:
2011–12.
- Fangfang Sun, Yanwei Lin, Xiaodong Wang, Yuan Gao, Shuang Ye.Paxlovid
in patients who are immunocompromised and hospitalised with SARS-CoV-2
infection. Lancet Infect Dis. 2022 Sep;22(9):1279.
- Elisabeth Mahase. Covid-19: Pfizer’s paxlovid is 89% effective in
patients at risk of serious illness, company reports. BMJ,2021 Nov
8;375: n2713.
- Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs. placebo and
clinical deterioration in outpatients with symptomatic COVID-19: a
randomized clinical trial. JAMA. 2020;324(22):2292–2300.
- Zhang Y, Li H, Zhang J, et al. The clinical characteristics and
outcomes of diabetes mellitus and secondary hyperglycaemia patients
with coronavirus disease 2019: A single-centre, retrospective,
observational study in Wuhan. Diabetes Obes Metab. 2020.
- Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated
with a higher risk of mortality than known diabetes in hospitalized
patients with COVID-19. Diabetes Obes Metab. 2020; 22(10): 1897- 1906.
- National Health Commission of the People’s Republic of China.
Diagnosis and treatment plan for COVID-19 (trial version 9). Int J
Epidemiol Infect Dis 2022; 49: 73–80.
- Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for
High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022;
386:1397-408.
- A living WHO guideline on drugs for covid-19. BMJ 2022; 377: o1045.
- Y. Mo, K. K.W. To, R. Zhou, et al. Mitochondrial dysfunction
associates with acute T lymphocytopenia and impaired functionality in
COVID-19 patients. Front. Immunol. 2021(12), 799896.
- L. Gibellini, S. DeBiasi, A. Paolini, et al. Altered bioenergetics and
mitochondrial dysfunction of monocytes in patients with COVID-19
pneumonia. EMBO Mol. Med. 2020(12), e13001.
- X. Gao, B. Zhu, Y. Wu, et al. TFAM-dependent mitochondrial metabolism
is required for alveolar macrophage maintenance and homeostasis. J.
Immunol. 2022(208), 1456–1466.
- Bibo Zhu, Xiaoqin Wei, Harish Narasimhan et al. Inhibition of the
mitochondrial pyruvate carrier simultaneously mitigates
hyperinflammation and hyperglycemia in COVID-19. Sci Immunol.
2023(23); eadf 0348.